Form 4: Artiva Biotherapeutics Director Brian Daniels Granted Stock Options

Artiva Biotherapeutics, Inc. Director Brian Daniels was granted 13,750 stock options with an exercise price of $1.61, vesting by June 24, 2026, or the 2026 annual stockholder meeting.

Summary

• Brian Daniels, a Director of Artiva Biotherapeutics, Inc. (ARTV), was granted 13,750 Director Stock Options on June 24, 2025.
• The options have an exercise price of $1.61 per share.
• The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
• The options are set to expire on June 23, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management interests with shareholder value, indicating confidence in future performance. It's a standard compensation practice and not indicative of negative underlying issues.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The exercise price of $1.61 provides a clear benchmark for future stock performance relative to the grant date.

Risks

• The value of the stock options is entirely dependent on the future market price of Artiva Biotherapeutics, Inc. common stock exceeding the exercise price of $1.61.
• If the stock price does not rise above the exercise price, the options may expire worthless, providing no financial benefit to the holder.

Future Outlook

The granting of these stock options indicates a long-term incentive for Director Brian Daniels, aligning his future compensation with the company's stock performance through June 2035. This is a standard mechanism to encourage long-term commitment and value creation.

Industry Context

This transaction is a standard form of equity compensation for directors in the biotechnology and pharmaceutical industries, aiming to align leadership interests with long-term shareholder value creation. Such grants are common for companies seeking to retain and incentivize experienced board members, particularly in sectors with long development cycles and high capital requirements.

Comparison to Industry Standards

• The grant of 13,750 stock options to a director is a common practice in the biotechnology sector for incentivizing board members.
• The specific number and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide specific comparable companies or projects.
• The vesting schedule (full vesting by June 2026 or the 2026 annual meeting) is also typical for director grants, providing a medium-term incentive that encourages sustained performance.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially incentivizing decisions that increase stock value. The potential for future dilution from option exercise is a long-term consideration, but this specific grant is relatively small.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The options will vest on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
• Brian Daniels may exercise these options at any time after vesting and before the expiration date of June 23, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

Artiva Biotherapeutics, ARTV, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology, Pharmaceuticals